Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis.
Oliva S et al. Oncotarget. 2016 Oct 13. doi: 10.18632/oncotarget.12641. [Epub ahead of print].
The role of 68Ga-DOTA-TATE PET/CT scanning in the evaluation of patients with multiple myeloma: preliminary results.
Sonmezoglu K et al. Nucl Med Commun. 2016 Oct 21. [Epub ahead of print].
Whole body magnetic resonance imaging in newly diagnosed multiple myeloma: early changes in lesional signal fat fraction predict disease response.
Latifoltojar A et al. Br J Haematol. 2016 Oct 21. doi: 10.1111/bjh.14401. [Epub ahead of print].
The possible role of burden of therapy on the risk of myeloma extramedullary spread.
Mangiacavalli S et al. Ann Hematol. 2016 Oct 21. [Epub ahead of print].
Extramedullary Plasmacytoma of the Gallbladder Detected on Fluorine 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
Fakhri AA et al. J Clin Imaging Sci. 2016 Sep 26;6:40. eCollection 2016.
Clinical significance of granule-containing myeloma cells in patients with newly diagnosed multiple myeloma.
Suzuki K et al. Cancer Med. 2016 Oct 13. doi: 10.1002/cam4.875. [Epub ahead of print].
Serum free light chains should be the target of response evaluation in light chain multiple myeloma rather than urines.
Dejoie T et al. Blood. 2016 Oct 11. pii: blood-2016-07-726778. [Epub ahead of print].
High applicability of ASO-RQPCR for detection of minimal residual disease in multiple myeloma by entirely patient-specific primers/probes.
Bai Y et al. J Hematol Oncol. 2016 Oct 11;9(1):107.
Identification of miRSNPs associated with the risk of multiple myeloma.
Macauda A et al. Int J Cancer. 2016 Oct 8. doi: 10.1002/ijc.30465. [Epub ahead of print].
High levels of periostin correlate with increased fracture rate, diffuse MRI pattern, abnormal bone remodeling and advanced disease stage in patients with newly diagnosed symptomatic multiple myeloma.
Terpos E et al. Blood Cancer J. 2016 Oct 7;6(10):e482. doi: 10.1038/bcj.2016.90.
A new ten-gene risk fraction model serving as prognostic indicator for clinical outcome of multiple myeloma.
Hu AX et al. Tumour Biol. 2016 Oct 5. [Epub ahead of print].
Benefits of new immunoglobulin-derived biomarkers for the diagnosis and follow-up of patients with dysglobulinemia.
Ermak N et al. Ann Biol Clin (Paris). 2016 Oct 1;74(5):597-605.
Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma.
McDonald JE et al. Clin Cancer Res. 2016 Oct 3. pii: clincanres.0235.2016. [Epub ahead of print].
Predicting PD-L1 expression on human cancer cells using next-generation sequencing information in computational simulation models.
Lanzel EA et al. Cancer Immunol Immunother. 2016 Sep 29. [Epub ahead of print].